+4.6%
TSLA vs MRNA
+511.3%
-506.7%
-39.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.9% | -2.2% | -3.7% | -5.8% |
| 7D | +1.5% | +5.5% | -4.0% | +1.3% |
| 30D | +10.1% | +158.7% | -148.6% | +2.7% |
| 3M | -15.4% | +182.1% | -197.5% | -22.3% |
| 6M | -12.8% | +151.8% | -164.6% | -19.8% |
| YTD | -21.3% | +393.6% | -414.8% | -27.7% |
| 1Y | +4.6% | +499.5% | -494.9% | -4.1% |
| All | +4.6% | +511.3% | -506.7% | -4.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling